Freelance journalist
Freelance technology writer, he writes about gadgets at BoingBoing.net
PROFILE
Joel Johnson
Guest
FROM Joel Johnson
To the Point
Rationale Behind the iPhone Price Cut Few gadgets have received as much hype as Apple's iPhone . Just introduced three months ago, people lined up for hours despite the cellphone's whopping top price of $599. Now, Apple's stock price has tumbled following a $200 price cut for the phone. Has Steve Jobs got more up his sleeve? Freelance journalist Joel Johnson, who writes about technology on BoingBoing.net , has an update on the iPhone, the electronics market and Apple's virtual music venture with Starbucks.
Recommended
To the Point
The Trump agenda: where's the beef? President Trump says big things are happening. After celebrating a House bill on health care, he doesn’t yet have Senate agreement. With James Comey’s public testimony scheduled tomorrow, the President today tweeted his selection of a new FBI Director. Is the Chief Executive all style and no substance? Later, terror attacks in Iran and conflicting claims about who’s behind them.
To the Point
What happens when America retreats from the world? Is President Trump taking his "America First" agenda to extremes, withdrawing the country from the international stage on trade and climate change, distancing America from its traditional allies across the Atlantic and even threatening to physically isolate the country through the building of a wall along its southern border? León Krauze guest hosts.
To the Point
Venezuela spirals into economic and political chaos Venezuela, a country whose potential for prosperity is unmatched, finds itself on the verge of civil war. What sustains the repressive government? With time running out, guest host León Krauze looks at what the international community can do to pull the country from the edge of collapse.
To the Point
Who's to blame for the opioid crisis? Some of the lawyers who took on Big Tobacco are now going after Big Pharma. It’s all about the deadly epidemic of opioid use. Are the drug companies to blame? What about the users? Later, on today’s Talking Point: making sense of Britain’s upset election.